Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Asset disposition
Director departure
|
|
ENZON PHARMACEUTICALS, INC. (ENZN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/16/2023 |
4
| READ RANDOLPH C (Director) has filed a Form 4 on ENZON PHARMACEUTICALS, INC.|
Txns:
| Bought 15,000 shares
@ $0.1325, valued at
$2k
Bought 84,550 shares
@ $0.141, valued at
$11.9k
|
|
| 05/05/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/20/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/20/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/20/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 01/06/2023 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/21/2022 |
3
| Firestone Jaffrey Adam (Director) has filed a Form 3 on ENZON PHARMACEUTICALS, INC. |
| 06/15/2022 |
8-K
| Quarterly results |
| 04/26/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/22/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/22/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/25/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 11/05/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 08/17/2021 |
4
| COUCHMAN JONATHAN (10% Owner) has filed a Form 4 on ENZON PHARMACEUTICALS, INC.|
Txns:
| Sold 50,000 shares
@ $0.3898, valued at
$19.5k
Sold 57,500 shares
@ $0.3898, valued at
$22.4k
|
|
| 08/05/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 06/08/2021 |
8-A12G/A
| Form 8-A12G/A - Registration of securities [Section 12(g)]: [Amend] |
| 06/08/2021 |
8-K
| Quarterly results |
| 05/04/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 04/14/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/14/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/02/2021 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/23/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 01/04/2021 |
8-K
| Quarterly results |
| 12/21/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 11/24/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/18/2020 |
4
| READ RANDOLPH C (Director) has filed a Form 4 on ENZON PHARMACEUTICALS, INC.|
Txns:
| Bought 50,450 shares
@ $0.1511, valued at
$7.6k
Bought 50,000 shares
@ $0.1575, valued at
$7.9k
|
|
| 11/17/2020 |
4
| Bleznick Jordan (Director) has filed a Form 4 on ENZON PHARMACEUTICALS, INC.|
Txns:
| Bought 100,000 shares
@ $0.1538, valued at
$15.4k
|
|
| 11/12/2020 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 11/09/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 11/03/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/03/2020 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|
|
|